Köhler A, Eggers H, Kuczyk M A, Schrader A J, Steffens S
Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover.
Aktuelle Urol. 2013 Nov;44(6):452-5. doi: 10.1055/s-0033-1358677. Epub 2013 Nov 20.
C-reactive protein (CRP) is an unspecific marker of systemic inflammation. It is known to be elevated in autoimmune disease, traumata and malignancies. Increased CRP levels have specifically been shown to be associated with disease progression and prognosis in various studies on renal cell carcinoma and transitional cell carcinoma. Although CRP, unlike PSA, is neither organ-specific nor tumour-specific, studies were able to show that increased CRP values are an independent prognostic marker for tumour-specific survival of patients with prostate cancer. In metastatic and castration-resistant prostate cancer elevated CRP levels have been approved as a useful marker to estimate the extent of disease and mortality. CRP measurements in serum are standardised worldwide and widely used in daily clinical routine. However, until CRP can be firmly established as a prognostic marker in daily routine, we need validation of its prognostic and predictive value with large and preferably prospective multicentre studies.
C反应蛋白（CRP）是全身炎症的非特异性标志物。已知其在自身免疫性疾病、创伤和恶性肿瘤中会升高。在关于肾细胞癌和移行细胞癌的各种研究中，CRP水平升高已被明确证明与疾病进展和预后相关。尽管与前列腺特异性抗原（PSA）不同，CRP既不是器官特异性的，也不是肿瘤特异性的，但研究表明，CRP值升高是前列腺癌患者肿瘤特异性生存的独立预后标志物。在转移性和去势抵抗性前列腺癌中，CRP水平升高已被认可为评估疾病范围和死亡率的有用标志物。血清CRP检测在全球范围内标准化，广泛应用于日常临床实践。然而，在CRP能够在日常实践中被牢固确立为预后标志物之前，我们需要通过大规模且最好是前瞻性的多中心研究来验证其预后和预测价值。
